ReviewOncogene2002
Genetic mechanisms of hepatocarcinogenesis.
Review in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 323 citations in OpenAlex.
- A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma.Irish journal of medical science · 2026Pooled it
- Prognostic value of Wnt inhibitory factor-1 expression in hepatocellular carcinoma that is independent of gene methylation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Trial
- Article
- Functional Role of COP1 Gene in Hepatocellular Carcinoma Lipid Metabolism and Stemness.Genes to cells : devoted to molecular & cellular mechanisms · 2026Article
- Hepatocellular carcinoma in a transplanted donor liver and colon cancer developing in a patient with a complex background: A case report.Oncology letters · 2024Article
- Seroprevalence of hepatitis B and C viruses among waste handlers in Ethiopia: A systematic review and meta-analysis.SAGE open medicine · 2024Review
- Hydrogen sulfide suppresses HMedical oncology (Northwood, London, England) · 2023Article
- RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues.Molecular oncology · 2022Article
- Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma.World journal of gastroenterology · 2022Review
- Three-Dimensional Aggregated Spheroid Model of Hepatocellular Carcinoma Using a 96-Pillar/Well Plate.Molecules (Basel, Switzerland) · 2021Article
- Interpreting the Molecular Mechanisms of Yinchenhao Decoction on Hepatocellular Carcinoma through Absorbed Components Based on Network Pharmacology.BioMed research international · 2021Article
- Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.Clinical and molecular hepatology · 2020Article
- A Case Report: Can Citrin Deficiency Lead to Hepatocellular Carcinoma in Children?Frontiers in pediatrics · 2019Article
- Integrating Network Pharmacology and Pharmacological Evaluation for Deciphering the Action Mechanism of Herbal Formula Zuojin Pill in Suppressing Hepatocellular Carcinoma.Frontiers in pharmacology · 2019Article
- DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: Implication of TGF-β1.PloS one · 2019Article
- Zeaxanthin Dipalmitate in the Treatment of Liver Disease.Evidence-based complementary and alternative medicine : eCAM · 2019Review
- Molecular Targets in Hepatocarcinogenesis and Implications for Therapy.Journal of clinical medicine · 2018Review
- Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2018Article
- Detection of a lipid peroxidation-induced DNA adduct across liver disease stages.Hepatobiliary surgery and nutrition · 2018Article
- Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The development of hepatocellular carcinoma (HCC) is a multistep process associated with changes in host gene expression, some of which correlate with the appearance and progression of tumor. Preneoplastic changes in gene expression result from altered DNA methylation, the actions of hepatitis B and C viruses, and point mutations or loss of heterozygosity (LOH) in selected cellular genes. Tumor progression is characterized by LOH involving tumor suppressor genes on many chromosomes and by gene amplification of selected oncogenes. The changes observed in different HCC nodules are often distinct, suggesting heterogeneity on the molecular level. These observations suggest that there are multiple, perhaps redundant negative growth regulatory pathways that protect cells against transformation. An understanding of the molecular pathogenesis of HCC may provide new markers for tumor staging, for assessment of the relative risk of tumor formation, and open new opportunities for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.